Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Lancet Oncol. 2016 Dec 5;18(1):42–51. doi: 10.1016/S1470-2045(16)30565-4

Figure 1. Waterfall plot showing best change in tumour burden from baseline at active treatment doses (n=60).

Figure 1

Investigator-assessed best change from baseline was the change in the sum of longest diameters of target lesions for patients treated with rovalpituzumab tesirine 0·2 mg/kg or 0·4 mg/kg every 3 weeks or 0·3 mg/kg or 0·4 mg/kg every 6 weeks. Grey dotted line at 20% indicates the threshold for progressive disease and the line at –30% the threshold for partial response. One patient did not have a measurable target lesion.

HHS Vulnerability Disclosure